Plasma proteomics analysis of patients with chronic spontaneous urticaria reveals significant associations with key disease characteristics but not with response to omalizumab treatment

Allergy. 2024 Sep;79(9):2547-2550. doi: 10.1111/all.16175. Epub 2024 May 26.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Anti-Allergic Agents* / therapeutic use
  • Biomarkers / blood
  • Chronic Urticaria* / blood
  • Chronic Urticaria* / drug therapy
  • Female
  • Humans
  • Male
  • Middle Aged
  • Omalizumab* / therapeutic use
  • Proteome
  • Proteomics* / methods
  • Treatment Outcome

Substances

  • Omalizumab
  • Anti-Allergic Agents
  • Biomarkers
  • Proteome